| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oropharyngeal Neoplasms | 105 | 2023 | 1108 | 12.920 |
Why?
|
| Papillomavirus Infections | 81 | 2023 | 978 | 9.940 |
Why?
|
| Head and Neck Neoplasms | 164 | 2024 | 3975 | 8.520 |
Why?
|
| Carcinoma, Squamous Cell | 164 | 2023 | 5435 | 8.110 |
Why?
|
| Human papillomavirus 16 | 46 | 2022 | 256 | 4.670 |
Why?
|
| Papillomaviridae | 35 | 2023 | 612 | 4.040 |
Why?
|
| Thyroid Neoplasms | 43 | 2020 | 1867 | 4.000 |
Why?
|
| Polymorphism, Single Nucleotide | 75 | 2022 | 4556 | 3.230 |
Why?
|
| Alphapapillomavirus | 14 | 2022 | 171 | 3.170 |
Why?
|
| Polymorphism, Genetic | 50 | 2016 | 1448 | 3.010 |
Why?
|
| Alcohol Drinking | 37 | 2024 | 553 | 2.900 |
Why?
|
| Smoking | 56 | 2024 | 2444 | 2.860 |
Why?
|
| Mouth Neoplasms | 22 | 2020 | 714 | 2.590 |
Why?
|
| Genetic Predisposition to Disease | 87 | 2022 | 5539 | 2.520 |
Why?
|
| Salivary Gland Neoplasms | 12 | 2016 | 489 | 2.460 |
Why?
|
| Case-Control Studies | 109 | 2024 | 6104 | 2.130 |
Why?
|
| Middle Aged | 278 | 2023 | 86494 | 1.930 |
Why?
|
| Male | 291 | 2023 | 123293 | 1.690 |
Why?
|
| Genotype | 79 | 2022 | 4108 | 1.660 |
Why?
|
| Risk Factors | 115 | 2024 | 17611 | 1.560 |
Why?
|
| Carcinoma, Papillary | 16 | 2018 | 584 | 1.550 |
Why?
|
| Carcinoma | 22 | 2022 | 2582 | 1.540 |
Why?
|
| Female | 293 | 2023 | 142255 | 1.540 |
Why?
|
| Neoplasms, Second Primary | 17 | 2016 | 1350 | 1.530 |
Why?
|
| Humans | 368 | 2024 | 262220 | 1.450 |
Why?
|
| Laryngeal Neoplasms | 19 | 2023 | 515 | 1.430 |
Why?
|
| DNA Repair | 24 | 2017 | 1871 | 1.400 |
Why?
|
| Vaccination | 5 | 2022 | 1125 | 1.390 |
Why?
|
| Aged | 192 | 2023 | 70357 | 1.360 |
Why?
|
| Adult | 187 | 2023 | 78112 | 1.350 |
Why?
|
| Pharyngeal Neoplasms | 10 | 2013 | 133 | 1.340 |
Why?
|
| Papillomavirus Vaccines | 8 | 2022 | 195 | 1.310 |
Why?
|
| Antibodies, Viral | 5 | 2020 | 1316 | 1.210 |
Why?
|
| Incidence | 32 | 2021 | 5712 | 1.190 |
Why?
|
| Anus Neoplasms | 5 | 2022 | 412 | 1.160 |
Why?
|
| Neoplasm Recurrence, Local | 37 | 2023 | 10070 | 1.140 |
Why?
|
| DNA-Binding Proteins | 25 | 2018 | 4788 | 1.120 |
Why?
|
| Neck Dissection | 9 | 2020 | 290 | 0.990 |
Why?
|
| fas Receptor | 6 | 2016 | 185 | 0.970 |
Why?
|
| Aged, 80 and over | 93 | 2021 | 29996 | 0.950 |
Why?
|
| Promoter Regions, Genetic | 22 | 2017 | 3076 | 0.910 |
Why?
|
| Tongue Neoplasms | 6 | 2020 | 246 | 0.900 |
Why?
|
| MicroRNAs | 17 | 2019 | 2955 | 0.880 |
Why?
|
| Mouth Diseases | 3 | 2023 | 35 | 0.880 |
Why?
|
| Genetic Variation | 16 | 2018 | 2090 | 0.880 |
Why?
|
| DNA, Viral | 7 | 2020 | 675 | 0.870 |
Why?
|
| Tumor Virus Infections | 4 | 2019 | 217 | 0.850 |
Why?
|
| Nasopharyngeal Neoplasms | 4 | 2016 | 325 | 0.830 |
Why?
|
| Prognosis | 51 | 2023 | 21744 | 0.820 |
Why?
|
| Uterine Cervical Neoplasms | 9 | 2022 | 1833 | 0.810 |
Why?
|
| Genes, BRCA1 | 3 | 2017 | 387 | 0.800 |
Why?
|
| Retrospective Studies | 70 | 2023 | 38020 | 0.790 |
Why?
|
| Thyroidectomy | 8 | 2020 | 486 | 0.790 |
Why?
|
| Hemangiosarcoma | 5 | 2023 | 235 | 0.780 |
Why?
|
| Sexual Behavior | 3 | 2018 | 309 | 0.780 |
Why?
|
| Lymphocytes | 12 | 2020 | 1228 | 0.770 |
Why?
|
| Carcinoma, Adenoid Cystic | 4 | 2011 | 421 | 0.760 |
Why?
|
| Neoplasms, Radiation-Induced | 5 | 2011 | 389 | 0.760 |
Why?
|
| Adenocarcinoma, Follicular | 4 | 2018 | 132 | 0.750 |
Why?
|
| Neoplasm Staging | 31 | 2019 | 13670 | 0.740 |
Why?
|
| Radiotherapy, Intensity-Modulated | 14 | 2021 | 2107 | 0.730 |
Why?
|
| Oropharynx | 5 | 2017 | 74 | 0.720 |
Why?
|
| Penile Neoplasms | 2 | 2021 | 161 | 0.710 |
Why?
|
| Odds Ratio | 29 | 2016 | 2326 | 0.700 |
Why?
|
| Early Detection of Cancer | 5 | 2021 | 1267 | 0.700 |
Why?
|
| Logistic Models | 25 | 2017 | 3450 | 0.700 |
Why?
|
| Genes, p16 | 3 | 2016 | 124 | 0.700 |
Why?
|
| 3' Untranslated Regions | 10 | 2019 | 345 | 0.700 |
Why?
|
| Xerostomia | 5 | 2022 | 190 | 0.690 |
Why?
|
| Texas | 23 | 2021 | 6309 | 0.690 |
Why?
|
| Gamma Rays | 3 | 2005 | 242 | 0.680 |
Why?
|
| Tobacco Products | 1 | 2020 | 120 | 0.660 |
Why?
|
| Adolescent | 60 | 2023 | 31262 | 0.650 |
Why?
|
| Lymph Nodes | 10 | 2019 | 2969 | 0.640 |
Why?
|
| DNA Helicases | 6 | 2018 | 435 | 0.640 |
Why?
|
| Genes, p53 | 10 | 2013 | 1093 | 0.620 |
Why?
|
| Disease-Free Survival | 31 | 2020 | 10023 | 0.620 |
Why?
|
| Smoking Cessation | 4 | 2020 | 714 | 0.620 |
Why?
|
| Mass Screening | 3 | 2021 | 1505 | 0.610 |
Why?
|
| Social Class | 3 | 2014 | 311 | 0.610 |
Why?
|
| Laryngectomy | 7 | 2023 | 241 | 0.590 |
Why?
|
| Sex Distribution | 8 | 2019 | 496 | 0.580 |
Why?
|
| Risk | 29 | 2017 | 1974 | 0.570 |
Why?
|
| Fanconi Anemia | 1 | 2017 | 88 | 0.570 |
Why?
|
| Nuclear Proteins | 16 | 2017 | 3317 | 0.570 |
Why?
|
| Oncogene Proteins, Viral | 5 | 2018 | 132 | 0.560 |
Why?
|
| Follow-Up Studies | 32 | 2021 | 14907 | 0.560 |
Why?
|
| Risk Assessment | 24 | 2020 | 6896 | 0.560 |
Why?
|
| Survival Analysis | 23 | 2019 | 9197 | 0.550 |
Why?
|
| Global Health | 6 | 2018 | 665 | 0.550 |
Why?
|
| Cancer Survivors | 7 | 2022 | 650 | 0.550 |
Why?
|
| Young Adult | 44 | 2020 | 21503 | 0.540 |
Why?
|
| Prevalence | 14 | 2023 | 3270 | 0.540 |
Why?
|
| In Situ Hybridization | 5 | 2018 | 1033 | 0.540 |
Why?
|
| Kaplan-Meier Estimate | 20 | 2020 | 6223 | 0.530 |
Why?
|
| Tobacco Use Disorder | 3 | 2013 | 284 | 0.530 |
Why?
|
| Oral Hygiene | 1 | 2015 | 20 | 0.520 |
Why?
|
| Oral Health | 1 | 2015 | 19 | 0.520 |
Why?
|
| Haplotypes | 10 | 2012 | 866 | 0.520 |
Why?
|
| DNA Breaks, Double-Stranded | 4 | 2017 | 320 | 0.520 |
Why?
|
| Neoplasms, Squamous Cell | 3 | 2011 | 86 | 0.510 |
Why?
|
| Proportional Hazards Models | 16 | 2023 | 5010 | 0.510 |
Why?
|
| Lymphatic Metastasis | 15 | 2019 | 4846 | 0.510 |
Why?
|
| Age Distribution | 9 | 2018 | 703 | 0.500 |
Why?
|
| Glutathione Transferase | 5 | 2010 | 357 | 0.500 |
Why?
|
| United States | 31 | 2021 | 15562 | 0.500 |
Why?
|
| Neoadjuvant Therapy | 7 | 2020 | 4980 | 0.500 |
Why?
|
| Survival Rate | 24 | 2020 | 12240 | 0.490 |
Why?
|
| Cohort Studies | 26 | 2020 | 9288 | 0.490 |
Why?
|
| Prospective Studies | 22 | 2023 | 12923 | 0.490 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 7 | 2017 | 506 | 0.470 |
Why?
|
| Tumor Suppressor Proteins | 12 | 2013 | 1826 | 0.470 |
Why?
|
| Osteosarcoma | 4 | 2009 | 921 | 0.470 |
Why?
|
| Tumor Suppressor Protein p14ARF | 5 | 2013 | 97 | 0.450 |
Why?
|
| Cotinine | 3 | 2008 | 41 | 0.450 |
Why?
|
| Endonucleases | 5 | 2013 | 178 | 0.450 |
Why?
|
| Human papillomavirus 18 | 3 | 2018 | 43 | 0.440 |
Why?
|
| Temporal Bone | 2 | 2012 | 101 | 0.440 |
Why?
|
| Reference Values | 10 | 2017 | 1098 | 0.440 |
Why?
|
| Free Tissue Flaps | 4 | 2022 | 372 | 0.430 |
Why?
|
| Facial Neoplasms | 2 | 2010 | 84 | 0.430 |
Why?
|
| Vitamins | 1 | 2013 | 156 | 0.430 |
Why?
|
| Combined Modality Therapy | 17 | 2023 | 8882 | 0.430 |
Why?
|
| Cross-Sectional Studies | 15 | 2023 | 4328 | 0.430 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 3 | 2020 | 260 | 0.430 |
Why?
|
| Self Report | 2 | 2017 | 766 | 0.420 |
Why?
|
| SEER Program | 6 | 2021 | 1000 | 0.420 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2019 | 2485 | 0.410 |
Why?
|
| Biomarkers, Tumor | 23 | 2020 | 10348 | 0.410 |
Why?
|
| Fas Ligand Protein | 4 | 2016 | 152 | 0.410 |
Why?
|
| Salivary Glands, Minor | 1 | 2011 | 33 | 0.410 |
Why?
|
| Histiocytoma, Malignant Fibrous | 2 | 2012 | 51 | 0.410 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2012 | 153 | 0.400 |
Why?
|
| Proton Therapy | 6 | 2020 | 1577 | 0.400 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2010 | 69 | 0.390 |
Why?
|
| Registries | 8 | 2016 | 2188 | 0.390 |
Why?
|
| Larynx, Artificial | 4 | 2012 | 43 | 0.390 |
Why?
|
| Family Health | 2 | 2011 | 326 | 0.380 |
Why?
|
| Tobacco Smoke Pollution | 3 | 2008 | 106 | 0.380 |
Why?
|
| Polymerase Chain Reaction | 15 | 2015 | 3190 | 0.380 |
Why?
|
| Genome-Wide Association Study | 9 | 2022 | 2267 | 0.380 |
Why?
|
| Skin Neoplasms | 8 | 2023 | 4656 | 0.380 |
Why?
|
| Bone Neoplasms | 4 | 2016 | 2560 | 0.380 |
Why?
|
| Sex Factors | 13 | 2018 | 2155 | 0.380 |
Why?
|
| Binding Sites | 12 | 2019 | 2170 | 0.380 |
Why?
|
| Treatment Outcome | 32 | 2023 | 33017 | 0.370 |
Why?
|
| Multivariate Analysis | 14 | 2015 | 4323 | 0.370 |
Why?
|
| Deglutition Disorders | 4 | 2020 | 448 | 0.370 |
Why?
|
| Hepatitis C, Chronic | 4 | 2019 | 451 | 0.370 |
Why?
|
| Gene Frequency | 14 | 2019 | 1165 | 0.360 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2018 | 293 | 0.360 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2017 | 2231 | 0.360 |
Why?
|
| Hepacivirus | 5 | 2020 | 398 | 0.360 |
Why?
|
| Osteoradionecrosis | 3 | 2017 | 123 | 0.350 |
Why?
|
| Intestinal Polyposis | 1 | 2009 | 30 | 0.350 |
Why?
|
| Genetic Association Studies | 13 | 2017 | 1083 | 0.350 |
Why?
|
| Jaw Neoplasms | 1 | 2009 | 16 | 0.350 |
Why?
|
| Codon | 8 | 2011 | 242 | 0.340 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2022 | 475 | 0.340 |
Why?
|
| Genital Neoplasms, Male | 1 | 2009 | 44 | 0.340 |
Why?
|
| Residence Characteristics | 1 | 2012 | 349 | 0.340 |
Why?
|
| Dietary Supplements | 1 | 2013 | 560 | 0.340 |
Why?
|
| Scalp | 1 | 2010 | 156 | 0.340 |
Why?
|
| Matched-Pair Analysis | 5 | 2014 | 103 | 0.340 |
Why?
|
| Chi-Square Distribution | 7 | 2011 | 1329 | 0.330 |
Why?
|
| Ear Canal | 1 | 2008 | 30 | 0.320 |
Why?
|
| Confidence Intervals | 9 | 2017 | 756 | 0.320 |
Why?
|
| Hepatitis C Antibodies | 2 | 2020 | 41 | 0.320 |
Why?
|
| Famous Persons | 1 | 2008 | 23 | 0.320 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2017 | 1487 | 0.320 |
Why?
|
| Primary Prevention | 2 | 2013 | 255 | 0.310 |
Why?
|
| Punctures | 4 | 2012 | 104 | 0.310 |
Why?
|
| Ear Neoplasms | 1 | 2008 | 59 | 0.310 |
Why?
|
| Diet | 3 | 2013 | 1449 | 0.310 |
Why?
|
| Thyroid Gland | 4 | 2020 | 353 | 0.310 |
Why?
|
| Cost-Benefit Analysis | 3 | 2020 | 948 | 0.310 |
Why?
|
| Age Factors | 14 | 2020 | 5385 | 0.310 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2009 | 221 | 0.300 |
Why?
|
| Immunohistochemistry | 10 | 2018 | 7545 | 0.300 |
Why?
|
| Re-Irradiation | 2 | 2020 | 163 | 0.290 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2008 | 130 | 0.290 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2022 | 803 | 0.290 |
Why?
|
| Occupational Exposure | 2 | 2008 | 246 | 0.290 |
Why?
|
| Liposarcoma | 1 | 2009 | 214 | 0.290 |
Why?
|
| Sarcoma | 5 | 2012 | 1725 | 0.280 |
Why?
|
| Cigarette Smoking | 2 | 2019 | 88 | 0.280 |
Why?
|
| Medicaid | 2 | 2019 | 286 | 0.280 |
Why?
|
| Sarcoma, Synovial | 1 | 2007 | 120 | 0.280 |
Why?
|
| Molecular Epidemiology | 2 | 2009 | 246 | 0.270 |
Why?
|
| Biopsy, Needle | 5 | 2017 | 1363 | 0.270 |
Why?
|
| Cell Cycle Proteins | 9 | 2019 | 2054 | 0.270 |
Why?
|
| Proteins | 3 | 2002 | 1953 | 0.260 |
Why?
|
| Hypopharyngeal Neoplasms | 3 | 2016 | 82 | 0.260 |
Why?
|
| Interleukin-1alpha | 2 | 2016 | 55 | 0.260 |
Why?
|
| Gastrostomy | 2 | 2015 | 180 | 0.260 |
Why?
|
| Tracheal Neoplasms | 1 | 2005 | 43 | 0.260 |
Why?
|
| Wound Healing | 1 | 2010 | 812 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 15881 | 0.260 |
Why?
|
| Neurothekeoma | 1 | 2005 | 10 | 0.260 |
Why?
|
| Secondary Prevention | 2 | 2020 | 333 | 0.260 |
Why?
|
| Protein C Inhibitor | 2 | 2016 | 4 | 0.260 |
Why?
|
| Carcinogens | 5 | 2014 | 382 | 0.260 |
Why?
|
| Disease Progression | 11 | 2015 | 6696 | 0.260 |
Why?
|
| Surgical Flaps | 2 | 2010 | 927 | 0.250 |
Why?
|
| E2F2 Transcription Factor | 2 | 2017 | 25 | 0.250 |
Why?
|
| Radiotherapy Dosage | 9 | 2020 | 3846 | 0.250 |
Why?
|
| Radiation Injuries | 5 | 2019 | 1412 | 0.250 |
Why?
|
| Radiotherapy, Conformal | 3 | 2020 | 902 | 0.250 |
Why?
|
| Socioeconomic Factors | 5 | 2015 | 1229 | 0.240 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2020 | 1268 | 0.240 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2015 | 3549 | 0.240 |
Why?
|
| Survivors | 6 | 2022 | 1034 | 0.240 |
Why?
|
| Exons | 6 | 2008 | 1326 | 0.240 |
Why?
|
| Papillomavirus E7 Proteins | 3 | 2013 | 63 | 0.240 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2014 | 1540 | 0.230 |
Why?
|
| G2 Phase | 1 | 2004 | 206 | 0.230 |
Why?
|
| Cost of Illness | 2 | 2020 | 502 | 0.230 |
Why?
|
| Repressor Proteins | 3 | 2013 | 1663 | 0.230 |
Why?
|
| Child | 17 | 2020 | 29115 | 0.230 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 601 | 0.230 |
Why?
|
| Prosthesis Failure | 4 | 2012 | 211 | 0.230 |
Why?
|
| DNA Adducts | 3 | 2010 | 211 | 0.230 |
Why?
|
| Cancer Care Facilities | 6 | 2020 | 884 | 0.230 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2022 | 691 | 0.230 |
Why?
|
| Neoplasms, Unknown Primary | 2 | 2018 | 192 | 0.230 |
Why?
|
| E2F1 Transcription Factor | 2 | 2016 | 197 | 0.230 |
Why?
|
| Quality Assurance, Health Care | 2 | 2020 | 590 | 0.230 |
Why?
|
| Pilot Projects | 7 | 2023 | 2801 | 0.220 |
Why?
|
| Oncogene Proteins | 1 | 2005 | 356 | 0.220 |
Why?
|
| Paclitaxel | 2 | 2011 | 1998 | 0.220 |
Why?
|
| Anus Diseases | 1 | 2022 | 29 | 0.220 |
Why?
|
| Genetic Loci | 2 | 2017 | 483 | 0.220 |
Why?
|
| Tonsillar Neoplasms | 2 | 2015 | 80 | 0.220 |
Why?
|
| Telomere | 2 | 2019 | 507 | 0.220 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 4 | 2013 | 69 | 0.220 |
Why?
|
| Rad51 Recombinase | 2 | 2017 | 125 | 0.210 |
Why?
|
| Smokers | 2 | 2020 | 144 | 0.210 |
Why?
|
| Vulvar Neoplasms | 2 | 2022 | 232 | 0.210 |
Why?
|
| Transcription Factors | 5 | 2013 | 5255 | 0.210 |
Why?
|
| Larynx | 1 | 2023 | 135 | 0.210 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 647 | 0.210 |
Why?
|
| Tinnitus | 1 | 2022 | 39 | 0.210 |
Why?
|
| Cocaine | 1 | 2024 | 236 | 0.210 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 711 | 0.200 |
Why?
|
| Behavior Therapy | 1 | 2004 | 295 | 0.200 |
Why?
|
| Chemoradiotherapy | 8 | 2019 | 1947 | 0.200 |
Why?
|
| Hypoparathyroidism | 2 | 2020 | 49 | 0.200 |
Why?
|
| Epidemics | 2 | 2013 | 64 | 0.200 |
Why?
|
| Postoperative Complications | 10 | 2022 | 5567 | 0.200 |
Why?
|
| Surveys and Questionnaires | 9 | 2021 | 5713 | 0.200 |
Why?
|
| Marijuana Smoking | 2 | 2013 | 40 | 0.200 |
Why?
|
| Triage | 2 | 2020 | 251 | 0.200 |
Why?
|
| Mouthwashes | 1 | 2021 | 41 | 0.200 |
Why?
|
| Speech, Alaryngeal | 2 | 2011 | 24 | 0.200 |
Why?
|
| Voice Disorders | 1 | 2021 | 39 | 0.200 |
Why?
|
| Watchful Waiting | 2 | 2021 | 289 | 0.200 |
Why?
|
| Organ Transplantation | 1 | 2023 | 192 | 0.190 |
Why?
|
| Cisplatin | 3 | 2018 | 2432 | 0.190 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2021 | 1221 | 0.190 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2005 | 661 | 0.190 |
Why?
|
| Speech Disorders | 1 | 2021 | 91 | 0.190 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2005 | 856 | 0.190 |
Why?
|
| International Cooperation | 2 | 2013 | 323 | 0.190 |
Why?
|
| Quality of Life | 9 | 2022 | 4578 | 0.190 |
Why?
|
| Hearing Loss | 1 | 2022 | 155 | 0.190 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 2 | 2018 | 46 | 0.190 |
Why?
|
| Immunoglobulin G | 3 | 2015 | 1029 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2012 | 521 | 0.190 |
Why?
|
| Positron-Emission Tomography | 5 | 2014 | 2182 | 0.190 |
Why?
|
| Pharyngeal Diseases | 1 | 2020 | 53 | 0.180 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 2 | 2017 | 40 | 0.180 |
Why?
|
| Cranial Nerve Diseases | 1 | 2021 | 73 | 0.180 |
Why?
|
| Mass Vaccination | 1 | 2020 | 21 | 0.180 |
Why?
|
| Papanicolaou Test | 1 | 2021 | 130 | 0.180 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2020 | 34 | 0.180 |
Why?
|
| Tobacco Use | 2 | 2018 | 55 | 0.180 |
Why?
|
| Tumor Protein p73 | 8 | 2013 | 105 | 0.180 |
Why?
|
| Cutaneous Fistula | 1 | 2020 | 46 | 0.180 |
Why?
|
| Medical History Taking | 2 | 2011 | 176 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 1215 | 0.180 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 3 | 2009 | 62 | 0.180 |
Why?
|
| Vaginal Smears | 1 | 2021 | 182 | 0.180 |
Why?
|
| Endocrine System Diseases | 1 | 2020 | 83 | 0.180 |
Why?
|
| Direct Service Costs | 1 | 2019 | 12 | 0.180 |
Why?
|
| Caspase 3 | 2 | 2012 | 469 | 0.170 |
Why?
|
| Cetuximab | 2 | 2018 | 472 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2019 | 7567 | 0.170 |
Why?
|
| Apoptosis | 5 | 2016 | 7603 | 0.170 |
Why?
|
| RNA, Messenger | 7 | 2022 | 6131 | 0.170 |
Why?
|
| Health Personnel | 2 | 2021 | 631 | 0.170 |
Why?
|
| Multifactorial Inheritance | 1 | 2020 | 147 | 0.170 |
Why?
|
| Age of Onset | 3 | 2017 | 826 | 0.170 |
Why?
|
| Capsid Proteins | 2 | 2018 | 183 | 0.170 |
Why?
|
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2019 | 15 | 0.170 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2021 | 211 | 0.170 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2018 | 1237 | 0.170 |
Why?
|
| Markov Chains | 1 | 2019 | 175 | 0.170 |
Why?
|
| Glossectomy | 2 | 2011 | 40 | 0.170 |
Why?
|
| Carcinoma in Situ | 1 | 2022 | 485 | 0.170 |
Why?
|
| Neoplasm Proteins | 5 | 2013 | 3233 | 0.170 |
Why?
|
| Genital Neoplasms, Female | 2 | 2019 | 741 | 0.170 |
Why?
|
| Comorbidity | 5 | 2018 | 2394 | 0.170 |
Why?
|
| Academic Medical Centers | 3 | 2017 | 673 | 0.170 |
Why?
|
| World Health Organization | 2 | 2010 | 315 | 0.170 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1947 | 0.160 |
Why?
|
| History, 21st Century | 2 | 2013 | 442 | 0.160 |
Why?
|
| Alleles | 6 | 2013 | 2435 | 0.160 |
Why?
|
| Neck Muscles | 1 | 2018 | 39 | 0.160 |
Why?
|
| Population Surveillance | 2 | 2019 | 628 | 0.160 |
Why?
|
| Liver Neoplasms | 3 | 2020 | 4562 | 0.160 |
Why?
|
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 2 | 2008 | 96 | 0.160 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2017 | 10 | 0.160 |
Why?
|
| Anal Canal | 1 | 2019 | 237 | 0.160 |
Why?
|
| Betacoronavirus | 2 | 2020 | 524 | 0.160 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 2 | 2008 | 66 | 0.160 |
Why?
|
| Health Care Costs | 2 | 2020 | 677 | 0.150 |
Why?
|
| Patient Preference | 1 | 2020 | 221 | 0.150 |
Why?
|
| Fanconi Anemia Complementation Group L Protein | 1 | 2017 | 1 | 0.150 |
Why?
|
| Telomerase | 2 | 2011 | 524 | 0.150 |
Why?
|
| Fanconi Anemia Complementation Group E Protein | 1 | 2017 | 3 | 0.150 |
Why?
|
| Surgical Oncology | 1 | 2020 | 191 | 0.150 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2010 | 33 | 0.150 |
Why?
|
| Adenoma, Oxyphilic | 3 | 2012 | 82 | 0.150 |
Why?
|
| 5' Untranslated Regions | 3 | 2008 | 93 | 0.150 |
Why?
|
| Lymphopenia | 1 | 2020 | 199 | 0.150 |
Why?
|
| DNA, Neoplasm | 6 | 2012 | 1905 | 0.150 |
Why?
|
| Muscle Neoplasms | 1 | 2018 | 109 | 0.150 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2017 | 41 | 0.150 |
Why?
|
| Recombinases | 1 | 2017 | 35 | 0.150 |
Why?
|
| Enteral Nutrition | 2 | 2016 | 317 | 0.150 |
Why?
|
| Mouth | 1 | 2018 | 122 | 0.150 |
Why?
|
| Insurance, Health | 1 | 2019 | 251 | 0.150 |
Why?
|
| Child, Preschool | 7 | 2020 | 16245 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 8880 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 2421 | 0.150 |
Why?
|
| Tonsillectomy | 2 | 2016 | 102 | 0.150 |
Why?
|
| Men | 1 | 2016 | 9 | 0.150 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2017 | 75 | 0.140 |
Why?
|
| Microbiota | 1 | 2023 | 543 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2016 | 3891 | 0.140 |
Why?
|
| Antineoplastic Agents | 6 | 2020 | 14301 | 0.140 |
Why?
|
| Microsatellite Repeats | 4 | 2012 | 576 | 0.140 |
Why?
|
| Patient Selection | 3 | 2020 | 2061 | 0.140 |
Why?
|
| DNA Mutational Analysis | 3 | 2020 | 2280 | 0.140 |
Why?
|
| Radiotherapy | 2 | 2017 | 1827 | 0.140 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2016 | 9 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 587 | 0.140 |
Why?
|
| Salivary Gland Diseases | 2 | 2008 | 10 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2019 | 2027 | 0.140 |
Why?
|
| Cell Differentiation | 5 | 2012 | 4044 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 503 | 0.140 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2016 | 80 | 0.140 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2016 | 28 | 0.140 |
Why?
|
| DNA Glycosylases | 2 | 2008 | 92 | 0.140 |
Why?
|
| Neutrophils | 1 | 2020 | 834 | 0.140 |
Why?
|
| Thyroid Diseases | 2 | 2008 | 85 | 0.140 |
Why?
|
| Statistics, Nonparametric | 3 | 2017 | 980 | 0.140 |
Why?
|
| Body Mass Index | 4 | 2014 | 2213 | 0.140 |
Why?
|
| Elective Surgical Procedures | 1 | 2017 | 255 | 0.130 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2016 | 94 | 0.130 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 245 | 0.130 |
Why?
|
| Models, Theoretical | 1 | 2020 | 787 | 0.130 |
Why?
|
| Spouses | 1 | 2017 | 134 | 0.130 |
Why?
|
| Recombinational DNA Repair | 1 | 2016 | 80 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2018 | 447 | 0.130 |
Why?
|
| Vietnam | 1 | 2015 | 56 | 0.130 |
Why?
|
| Receptors, Odorant | 1 | 2015 | 47 | 0.130 |
Why?
|
| Health Promotion | 1 | 2019 | 501 | 0.130 |
Why?
|
| Sensitivity and Specificity | 4 | 2021 | 4976 | 0.130 |
Why?
|
| RNA Helicases | 1 | 2015 | 101 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 359 | 0.130 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2015 | 44 | 0.130 |
Why?
|
| Europe | 4 | 2011 | 647 | 0.130 |
Why?
|
| Helicobacter pylori | 1 | 2005 | 1292 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 437 | 0.130 |
Why?
|
| Helicobacter Infections | 1 | 2005 | 1213 | 0.130 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2018 | 491 | 0.130 |
Why?
|
| ROC Curve | 5 | 2020 | 1180 | 0.130 |
Why?
|
| Salvage Therapy | 4 | 2023 | 2060 | 0.130 |
Why?
|
| Hepatitis C | 1 | 2020 | 524 | 0.120 |
Why?
|
| Carboplatin | 3 | 2015 | 824 | 0.120 |
Why?
|
| Germ-Line Mutation | 2 | 2017 | 1047 | 0.120 |
Why?
|
| Causality | 2 | 2014 | 178 | 0.120 |
Why?
|
| Photons | 1 | 2018 | 507 | 0.120 |
Why?
|
| Thyroglobulin | 1 | 2014 | 62 | 0.120 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 666 | 0.120 |
Why?
|
| Zinc Fingers | 1 | 2015 | 205 | 0.120 |
Why?
|
| Consensus | 2 | 2020 | 1005 | 0.120 |
Why?
|
| Polymorphism, Restriction Fragment Length | 4 | 2011 | 239 | 0.120 |
Why?
|
| Heterozygote | 1 | 2017 | 1016 | 0.120 |
Why?
|
| Deglutition | 2 | 2020 | 171 | 0.120 |
Why?
|
| Pandemics | 2 | 2020 | 1562 | 0.120 |
Why?
|
| Education | 1 | 2014 | 112 | 0.120 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2013 | 44 | 0.120 |
Why?
|
| Research Design | 2 | 2019 | 1562 | 0.120 |
Why?
|
| Ethanol | 2 | 2022 | 265 | 0.120 |
Why?
|
| Robotic Surgical Procedures | 1 | 2020 | 483 | 0.120 |
Why?
|
| Receptors, Nicotinic | 1 | 2015 | 190 | 0.120 |
Why?
|
| Time Factors | 6 | 2020 | 12980 | 0.120 |
Why?
|
| DNA Repair Enzymes | 3 | 2011 | 237 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 1493 | 0.110 |
Why?
|
| Income | 1 | 2014 | 225 | 0.110 |
Why?
|
| Gastroesophageal Reflux | 2 | 2008 | 334 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 1041 | 0.110 |
Why?
|
| Linkage Disequilibrium | 2 | 2012 | 462 | 0.110 |
Why?
|
| Telomere Homeostasis | 1 | 2013 | 74 | 0.110 |
Why?
|
| Seroepidemiologic Studies | 2 | 2016 | 124 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2012 | 286 | 0.110 |
Why?
|
| Group Processes | 1 | 2012 | 53 | 0.110 |
Why?
|
| Epigenomics | 1 | 2014 | 265 | 0.110 |
Why?
|
| Dinucleotide Repeats | 1 | 2012 | 10 | 0.110 |
Why?
|
| Induction Chemotherapy | 2 | 2016 | 666 | 0.110 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 845 | 0.110 |
Why?
|
| Iodine Radioisotopes | 1 | 2014 | 373 | 0.110 |
Why?
|
| Skull Neoplasms | 1 | 2012 | 67 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2018 | 1177 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 3757 | 0.100 |
Why?
|
| Mandibular Diseases | 1 | 2012 | 44 | 0.100 |
Why?
|
| Epidemiologic Studies | 1 | 2012 | 60 | 0.100 |
Why?
|
| Regression Analysis | 3 | 2020 | 1550 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 2480 | 0.100 |
Why?
|
| Carotid Sinus | 1 | 2011 | 10 | 0.100 |
Why?
|
| Databases, Factual | 3 | 2020 | 2236 | 0.100 |
Why?
|
| Phosphoinositide Phospholipase C | 1 | 2011 | 13 | 0.100 |
Why?
|
| Urban Population | 1 | 2013 | 269 | 0.100 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2012 | 110 | 0.100 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 777 | 0.100 |
Why?
|
| Veterans | 2 | 2020 | 1654 | 0.100 |
Why?
|
| Pharyngectomy | 3 | 2020 | 44 | 0.100 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2017 | 716 | 0.100 |
Why?
|
| Neoplasm Metastasis | 4 | 2009 | 5123 | 0.100 |
Why?
|
| Bayes Theorem | 3 | 2021 | 1033 | 0.100 |
Why?
|
| Pneumonia, Aspiration | 1 | 2011 | 41 | 0.100 |
Why?
|
| Neoplasms | 3 | 2017 | 15198 | 0.100 |
Why?
|
| Rhabdomyosarcoma | 2 | 2006 | 342 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2015 | 638 | 0.100 |
Why?
|
| Ifosfamide | 1 | 2011 | 346 | 0.100 |
Why?
|
| Mandible | 1 | 2012 | 188 | 0.100 |
Why?
|
| Ultrasonography | 2 | 2014 | 1869 | 0.100 |
Why?
|
| Demography | 1 | 2012 | 437 | 0.100 |
Why?
|
| Rural Population | 1 | 2013 | 282 | 0.090 |
Why?
|
| Obesity | 2 | 2014 | 2892 | 0.090 |
Why?
|
| Biomarkers | 2 | 2020 | 5057 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2012 | 318 | 0.090 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 1750 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 60 | 0.090 |
Why?
|
| Overweight | 2 | 2014 | 486 | 0.090 |
Why?
|
| Observation | 1 | 2010 | 51 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2009 | 9 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2019 | 1425 | 0.090 |
Why?
|
| Interleukin-10 | 1 | 2013 | 485 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 5 | 2018 | 3983 | 0.090 |
Why?
|
| Linear Models | 2 | 2017 | 1090 | 0.090 |
Why?
|
| Analysis of Variance | 4 | 2020 | 2309 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2011 | 231 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 2631 | 0.090 |
Why?
|
| Caspase 8 | 1 | 2010 | 145 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2019 | 1340 | 0.090 |
Why?
|
| Speech Intelligibility | 1 | 2009 | 40 | 0.090 |
Why?
|
| Carcinoma, Basosquamous | 1 | 2009 | 12 | 0.090 |
Why?
|
| Thinness | 1 | 2010 | 82 | 0.090 |
Why?
|
| Patient Positioning | 1 | 2011 | 195 | 0.090 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 173 | 0.090 |
Why?
|
| Eye Neoplasms | 1 | 2011 | 247 | 0.080 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2009 | 73 | 0.080 |
Why?
|
| Marital Status | 1 | 2009 | 96 | 0.080 |
Why?
|
| Prosthesis Implantation | 4 | 2012 | 265 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 625 | 0.080 |
Why?
|
| Alcoholic Beverages | 1 | 2008 | 22 | 0.080 |
Why?
|
| Probability | 3 | 2010 | 868 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2012 | 291 | 0.080 |
Why?
|
| Nutrition Surveys | 2 | 2023 | 299 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 622 | 0.080 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 1067 | 0.080 |
Why?
|
| Aldehyde Dehydrogenase | 2 | 2011 | 105 | 0.080 |
Why?
|
| Otologic Surgical Procedures | 1 | 2008 | 33 | 0.080 |
Why?
|
| Poverty | 1 | 2012 | 472 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1165 | 0.080 |
Why?
|
| Microsurgery | 1 | 2010 | 244 | 0.080 |
Why?
|
| Genomic Instability | 1 | 2011 | 519 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 2288 | 0.080 |
Why?
|
| Dronabinol | 1 | 2008 | 36 | 0.080 |
Why?
|
| Health Services Research | 1 | 2009 | 233 | 0.080 |
Why?
|
| DNA Damage | 2 | 2007 | 1950 | 0.080 |
Why?
|
| Benzopyrenes | 1 | 2007 | 11 | 0.080 |
Why?
|
| History, 19th Century | 1 | 2008 | 155 | 0.080 |
Why?
|
| ADP Ribose Transferases | 1 | 2007 | 28 | 0.080 |
Why?
|
| Inclusion Bodies | 1 | 2007 | 76 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 1063 | 0.080 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2007 | 41 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 1016 | 0.080 |
Why?
|
| Parathyroid Glands | 1 | 2007 | 127 | 0.070 |
Why?
|
| Chromosomal Instability | 1 | 2008 | 234 | 0.070 |
Why?
|
| Immunoassay | 1 | 2008 | 215 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 11571 | 0.070 |
Why?
|
| Mutagens | 1 | 2007 | 186 | 0.070 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2007 | 366 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 763 | 0.070 |
Why?
|
| Mutagenesis, Insertional | 3 | 2016 | 218 | 0.070 |
Why?
|
| Heart Arrest | 1 | 2011 | 361 | 0.070 |
Why?
|
| Oxidoreductases | 1 | 2007 | 171 | 0.070 |
Why?
|
| Latin America | 3 | 2013 | 115 | 0.070 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2007 | 137 | 0.070 |
Why?
|
| Eyelid Neoplasms | 1 | 2008 | 191 | 0.070 |
Why?
|
| Genes, Retinoblastoma | 1 | 2006 | 86 | 0.070 |
Why?
|
| Cause of Death | 2 | 2020 | 756 | 0.070 |
Why?
|
| Glycine Hydroxymethyltransferase | 1 | 2005 | 9 | 0.070 |
Why?
|
| Medical Records | 1 | 2007 | 414 | 0.070 |
Why?
|
| Parents | 1 | 2012 | 1003 | 0.070 |
Why?
|
| Depression | 1 | 2016 | 1715 | 0.070 |
Why?
|
| Loss of Heterozygosity | 2 | 2004 | 603 | 0.070 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2008 | 304 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2008 | 575 | 0.070 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2005 | 14 | 0.070 |
Why?
|
| Mandibular Neoplasms | 1 | 2006 | 75 | 0.070 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2005 | 24 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8228 | 0.070 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2005 | 16 | 0.070 |
Why?
|
| Radiopharmaceuticals | 4 | 2013 | 1309 | 0.070 |
Why?
|
| Germany | 2 | 2016 | 112 | 0.060 |
Why?
|
| Trachea | 3 | 2011 | 259 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 77 | 0.060 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2005 | 76 | 0.060 |
Why?
|
| Thymidylate Synthase | 1 | 2004 | 53 | 0.060 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2005 | 103 | 0.060 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2005 | 60 | 0.060 |
Why?
|
| Homozygote | 3 | 2013 | 715 | 0.060 |
Why?
|
| Esophageal Neoplasms | 2 | 2016 | 3170 | 0.060 |
Why?
|
| Receptors, Calcitriol | 1 | 2005 | 133 | 0.060 |
Why?
|
| Sequence Deletion | 3 | 2016 | 875 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2010 | 1129 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 696 | 0.060 |
Why?
|
| Cell Death | 1 | 2006 | 672 | 0.060 |
Why?
|
| India | 1 | 2004 | 305 | 0.060 |
Why?
|
| Algorithms | 3 | 2020 | 3891 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 446 | 0.060 |
Why?
|
| Neck | 2 | 2022 | 382 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 2342 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2017 | 1392 | 0.060 |
Why?
|
| Esophagus | 3 | 2011 | 554 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 14558 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 4902 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 6042 | 0.060 |
Why?
|
| Infant | 2 | 2020 | 13300 | 0.060 |
Why?
|
| Genetic Markers | 3 | 2012 | 972 | 0.060 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2013 | 1766 | 0.050 |
Why?
|
| Parathyroid Neoplasms | 1 | 2004 | 185 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 378 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2005 | 371 | 0.050 |
Why?
|
| Fatigue | 2 | 2022 | 1239 | 0.050 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2022 | 11 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2022 | 22 | 0.050 |
Why?
|
| Awards and Prizes | 1 | 2004 | 98 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 727 | 0.050 |
Why?
|
| Cytokines | 1 | 2011 | 2823 | 0.050 |
Why?
|
| Decision Making | 1 | 2010 | 1295 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2010 | 2023 | 0.050 |
Why?
|
| Disease Management | 2 | 2018 | 1061 | 0.050 |
Why?
|
| Base Sequence | 4 | 2011 | 4887 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 4348 | 0.050 |
Why?
|
| DNA | 3 | 2023 | 2685 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2018 | 5598 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2007 | 2362 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 486 | 0.050 |
Why?
|
| Cocarcinogenesis | 2 | 2011 | 50 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2021 | 54 | 0.050 |
Why?
|
| Vagina | 1 | 2022 | 319 | 0.050 |
Why?
|
| Iceland | 1 | 2020 | 12 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 1957 | 0.050 |
Why?
|
| Radiation Tolerance | 1 | 2004 | 629 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 3632 | 0.050 |
Why?
|
| Health Behavior | 1 | 2004 | 602 | 0.040 |
Why?
|
| Models, Genetic | 2 | 2020 | 1111 | 0.040 |
Why?
|
| Skull Base Neoplasms | 1 | 2004 | 315 | 0.040 |
Why?
|
| Developing Countries | 1 | 2022 | 317 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2010 | 2812 | 0.040 |
Why?
|
| Occupational Health | 1 | 2020 | 95 | 0.040 |
Why?
|
| Penetrance | 1 | 2020 | 126 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 757 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 257 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2003 | 383 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 2021 | 251 | 0.040 |
Why?
|
| Parotid Gland | 1 | 2019 | 111 | 0.040 |
Why?
|
| Models, Biological | 3 | 2019 | 3242 | 0.040 |
Why?
|
| Survival | 1 | 2019 | 177 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 683 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 489 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2022 | 488 | 0.040 |
Why?
|
| Genitalia, Female | 1 | 2019 | 69 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 174 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 377 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2022 | 862 | 0.040 |
Why?
|
| Pharynx | 1 | 2019 | 153 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2018 | 137 | 0.040 |
Why?
|
| Oximes | 1 | 2019 | 176 | 0.040 |
Why?
|
| Formaldehyde | 1 | 2018 | 114 | 0.040 |
Why?
|
| Prosthesis Design | 2 | 2011 | 752 | 0.040 |
Why?
|
| Gene Expression | 3 | 2015 | 3563 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 226 | 0.040 |
Why?
|
| Computational Biology | 2 | 2020 | 1271 | 0.040 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 206 | 0.040 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2017 | 49 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 3264 | 0.040 |
Why?
|
| DNA Primers | 2 | 2011 | 1395 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 2303 | 0.040 |
Why?
|
| Pituitary Hormones | 1 | 2017 | 14 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 667 | 0.040 |
Why?
|
| Luciferases | 2 | 2011 | 444 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 315 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2018 | 178 | 0.040 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2017 | 21 | 0.040 |
Why?
|
| Time | 1 | 2017 | 179 | 0.040 |
Why?
|
| Epistasis, Genetic | 1 | 2017 | 119 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 350 | 0.040 |
Why?
|
| DEAD Box Protein 20 | 1 | 2016 | 1 | 0.040 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2016 | 74 | 0.040 |
Why?
|
| Hepatitis B, Chronic | 1 | 2018 | 137 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 565 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 293 | 0.040 |
Why?
|
| Viral Core Proteins | 1 | 2016 | 23 | 0.030 |
Why?
|
| Genomic Structural Variation | 1 | 2017 | 78 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2019 | 375 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2004 | 807 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2016 | 112 | 0.030 |
Why?
|
| Protein Array Analysis | 2 | 2011 | 499 | 0.030 |
Why?
|
| Hepatitis B | 1 | 2018 | 259 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2017 | 292 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2013 | 1064 | 0.030 |
Why?
|
| Medicare | 1 | 2021 | 896 | 0.030 |
Why?
|
| Melanoma | 3 | 2013 | 5320 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2009 | 500 | 0.030 |
Why?
|
| Recurrence | 2 | 2016 | 4784 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 858 | 0.030 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 1960 | 0.030 |
Why?
|
| Whole Genome Sequencing | 1 | 2017 | 336 | 0.030 |
Why?
|
| Genes, Reporter | 2 | 2009 | 798 | 0.030 |
Why?
|
| Organs at Risk | 1 | 2018 | 516 | 0.030 |
Why?
|
| Mucositis | 1 | 2015 | 148 | 0.030 |
Why?
|
| Stomatitis | 1 | 2016 | 183 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 7793 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 7719 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 490 | 0.030 |
Why?
|
| Biotransformation | 1 | 2014 | 94 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 651 | 0.030 |
Why?
|
| E2F Transcription Factors | 1 | 2014 | 131 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2022 | 1160 | 0.030 |
Why?
|
| Camptothecin | 1 | 2016 | 515 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 247 | 0.030 |
Why?
|
| Italy | 1 | 2014 | 236 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 784 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 1004 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2014 | 279 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2015 | 270 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 1102 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 868 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 344 | 0.030 |
Why?
|
| Surgeons | 1 | 2020 | 524 | 0.030 |
Why?
|
| Bilirubin | 1 | 2014 | 221 | 0.030 |
Why?
|
| Veterans Health | 1 | 2014 | 181 | 0.030 |
Why?
|
| Public Health | 1 | 2015 | 302 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 656 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 944 | 0.030 |
Why?
|
| Thyrotropin | 1 | 2012 | 117 | 0.030 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 420 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2013 | 137 | 0.030 |
Why?
|
| Thyroxine | 1 | 2012 | 116 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 3482 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 312 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2019 | 1234 | 0.030 |
Why?
|
| Vaginal Neoplasms | 1 | 2013 | 148 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2012 | 166 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1991 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 1284 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 2232 | 0.030 |
Why?
|
| Genome | 1 | 2016 | 678 | 0.030 |
Why?
|
| Aromatase | 1 | 2012 | 56 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 666 | 0.030 |
Why?
|
| Dermatofibrosarcoma | 1 | 2012 | 72 | 0.030 |
Why?
|
| Gonadotropins | 1 | 2012 | 49 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2013 | 221 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2013 | 185 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2013 | 299 | 0.030 |
Why?
|
| Reflex, Abnormal | 1 | 2011 | 20 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 1435 | 0.030 |
Why?
|
| Prolactin | 1 | 2012 | 154 | 0.030 |
Why?
|
| Radiography | 1 | 2016 | 1899 | 0.020 |
Why?
|
| Leukoplakia, Oral | 1 | 2011 | 70 | 0.020 |
Why?
|
| Americas | 1 | 2011 | 53 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 968 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2003 | 6063 | 0.020 |
Why?
|
| Ku Autoantigen | 1 | 2011 | 79 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2014 | 611 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2012 | 205 | 0.020 |
Why?
|
| Voice Quality | 1 | 2011 | 33 | 0.020 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2012 | 274 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2011 | 241 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2011 | 606 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 704 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2016 | 3022 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 427 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 1848 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2010 | 349 | 0.020 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2009 | 60 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2011 | 695 | 0.020 |
Why?
|
| Speech Production Measurement | 1 | 2009 | 17 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2009 | 40 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 405 | 0.020 |
Why?
|
| Beer | 1 | 2008 | 4 | 0.020 |
Why?
|
| Osteonecrosis | 1 | 2009 | 55 | 0.020 |
Why?
|
| Wine | 1 | 2008 | 19 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 5155 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2022 | 3349 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2012 | 740 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 2596 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 598 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 4746 | 0.020 |
Why?
|
| North America | 1 | 2009 | 313 | 0.020 |
Why?
|
| Comet Assay | 1 | 2007 | 57 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2017 | 1332 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2009 | 228 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2012 | 498 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2009 | 482 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2012 | 1016 | 0.020 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2007 | 87 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2011 | 548 | 0.020 |
Why?
|
| Mutation | 2 | 2019 | 15177 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2015 | 4303 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 15708 | 0.020 |
Why?
|
| Plasmids | 1 | 2009 | 834 | 0.020 |
Why?
|
| Radiation Effects | 1 | 2006 | 20 | 0.020 |
Why?
|
| Guanosine | 1 | 2006 | 22 | 0.020 |
Why?
|
| Transglutaminases | 1 | 2007 | 101 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2007 | 200 | 0.020 |
Why?
|
| Valine | 1 | 2007 | 176 | 0.020 |
Why?
|
| Thymidine | 1 | 2006 | 151 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2009 | 730 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 3817 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 2514 | 0.020 |
Why?
|
| HIV Infections | 1 | 2018 | 2133 | 0.020 |
Why?
|
| Length of Stay | 1 | 2012 | 1929 | 0.020 |
Why?
|
| No-Observed-Adverse-Effect Level | 1 | 2005 | 6 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2007 | 669 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 642 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 3529 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2005 | 42 | 0.020 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2005 | 118 | 0.020 |
Why?
|
| Phenotype | 2 | 2008 | 6259 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2006 | 243 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2009 | 983 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 2504 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2005 | 134 | 0.020 |
Why?
|
| Calcitriol | 1 | 2005 | 125 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 1615 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 2078 | 0.020 |
Why?
|
| Aldehyde Dehydrogenase, Mitochondrial | 1 | 2004 | 3 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2006 | 824 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 2004 | 137 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 5378 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2003 | 108 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 4769 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2005 | 573 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2002 | 176 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2003 | 232 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2003 | 290 | 0.010 |
Why?
|
| Contrast Media | 1 | 2009 | 1474 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 541 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 2373 | 0.010 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2002 | 109 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 5185 | 0.010 |
Why?
|
| Animals | 2 | 2017 | 59491 | 0.010 |
Why?
|
| Reoperation | 1 | 2004 | 1405 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 2282 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2007 | 2519 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 2006 | 1435 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 3879 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 4948 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 34393 | 0.010 |
Why?
|